Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Macrogenics (NQ: MGNX )

3.255 +0.045 (+1.40%)
Streaming Delayed Price Updated: 2:34 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Macrogenics

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Mid-Day Market Update: Gold Drops Over 2%; Leap Therapeutics Shares Jump
Midway through trading Thursday, the Dow traded down 0.74% to 34,557.75 while the NASDAQ fell 0.67% to 15,060.25. The S&P also fell, dropping 0.79% to 4,445.34. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why MacroGenics Stock Is Tanking Today
Investors weren't thrilled with the company's latest clinical data. 
Via The Motley Fool
38 Stocks Moving In Thursday's Mid-Day Session
Gainers IronNet Cybersecurity, Inc. (NASDAQ: IRNT) shares jumped 30.4% to $41.90 amid increased retail investor interest in the stock on social media. Dutch Bros Inc. (NYSE: BROS... 
Via Benzinga
Earnings Scheduled For April 29, 2021
Companies Reporting Before The Bell • OSI Systems (NASDAQ:OSIS) is estimated to report quarterly earnings at $1.33 per share on revenue of $290.51 million. •... 
Via Benzinga
Mid-Morning Market Update: Markets Down; US Retail Sales Unexpectedly Increase in August
Following the market opening Thursday, the Dow traded down 0.45% to 34,657.69 while the NASDAQ fell 0.66% to 15,061.97. The S&P also fell, dropping 0.62% to 4,453.04. The U.S... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Leap Therapeutics (NASDAQ:LPTX) stock rose 32.64% to $2.56 during Thursday's pre-market session. The company's market cap stands at $152.7 million. Phio... 
Via Benzinga
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest... 
Via Benzinga
Exposures COVID-19 Product Safety
Why MacroGenics Soared Nearly 9% Higher Today
Investors are signaling hope in the company's top drug, despite a disappointing final analysis. 
Via The Motley Fool
MacroGenics Stock Dives As Cancer Drug Shows Mixed Results Vs. Roche Blockbuster
A fully approved breast cancer drug from MacroGenics failed to pass muster in a final analysis, and MGNX stock dipped Wednesday. 
Via Investor's Business Daily
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
MacroGenics' Cancer Drug Margenza Flops On Overall Survival Analysis
MacroGenics Inc (NASDAQ: MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a head-to-head matchup with breast... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Cara Therapeutics (NASDAQ:CARA) ... 
Via Benzinga
Looking into Macrogenics's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Macrogenics's (NASDAQ:MGNX) reported sales totaled $30.76 million. Despite a 21.47% in earnings, the company posted a... 
Via Benzinga
MacroGenics (MGNX) Q2 2021 Earnings Call Transcript
MGNX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why MacroGenics Stock Is Tumbling Today
The company provided its Q2 update. 
Via The Motley Fool
NASDAQ:MGNX Long Term Investor Notice: Investigation of Potential Wrongdoing at MacroGenics, Inc.
San Diego, CA -- (SBWIRE) -- 06/22/2021 -- Certain directors of MacroGenics, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion
Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics ​​​worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong... 
Via Talk Markets
MacroGenics, Zai Lab Ink Over $1.4B Immuno-Oncology Development Deal
MacroGenics Inc (NASDAQ: MGNX) and Zai Lab Limited (NASDAQ: ZLAB) have entered into an exclusive collaboration and license agreement involving up to four... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Kindred Biosciences (NASDAQ:KIN) shares moved upwards by 45.26% to $9.21 during Wednesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Atossa Therapeutics (NASDAQ:ATOS)... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares surged 87.3% to close at $9.14 on Monday on abnormally-high session volume. EXFO Inc. (NASDAQ: EXFO) gained 60.3% to settle... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Windtree Therapeutics (NASDAQ:WINT) shares rose 35.85% to $2.69 during Friday's regular session. Trading volume for this security as of 12:30 EST is 117.5... 
Via Benzinga
64 Biggest Movers From Friday
Gainers Senseonics Holdings, Inc. (NYSE: SENS) jumped 42% to settle at $2.91 on Friday after the company disclosed results from a PROMISE study evaluating its Eversense CGM... 
Via Benzinga
40 Stocks Moving In Friday's Mid-Day Session
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares jumped 68.8% to $25.49 after gaining 23% on Thursday. Senseonics Holdings, Inc. (NYSE: SENS) gained 26% to $2.5817 after the... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
Why MacroGenics Stock Is Tumbling Today
The company announced preliminary phase 1 results for its tumor-fighting drug MGC018. 
Via The Motley Fool
MacroGenics (MGNX) Q1 2021 Earnings Call Transcript
MGNX earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.